We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.26B
AUM Growth
-$464M
Cap. Flow
+$97.5M
Cap. Flow %
4.32%
Top 10 Hldgs %
30.92%
Holding
158
New
12
Increased
35
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$50.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$28.2M
3
ZGNX
Zogenix, Inc.
ZGNX
+$21.7M
4
TLND
Talend S.A. American Depositary Shares
TLND
+$18.7M
5
TWLO icon
Twilio
TWLO
+$17.9M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$26.2M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$23.3M
3
MIC
Macquarie Infrastructure Holdings, LLC
MIC
+$19.7M
4
SLDB icon
Solid Biosciences
SLDB
+$18.9M
5
SNA icon
Snap-on
SNA
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 42.75%
2 Technology 23.08%
3 Consumer Discretionary 10.05%
4 Industrials 6.38%
5 Communication Services 2.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DOOR
76
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$7.62M 0.34%
170,000
– –
XNCR icon
77
Xencor
XNCR
$1.59B
$7.34M 0.32%
203,000
-25,000
-11% -$917K
EXR icon
78
Extra Space Storage
EXR
$31.3B
$7.24M 0.32%
80,000
– –
WVE icon
79
Wave Life Sciences
WVE
$1.11B
$7.16M 0.32%
170,400
– –
RARX
80
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.06M 0.31%
388,000
– –
THOR
81
DELISTED
Synthorx, Inc. Common Stock
THOR
$6.95M 0.31%
+400,000
New +$5.8M
MDCO
82
DELISTED
Medicines Co
MDCO
$6.41M 0.28%
+335,000
New +$7.79M
GWPH
83
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.18M 0.27%
63,500
– –
BOLD
84
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.86M 0.26%
275,000
– –
RGEN icon
85
Repligen
RGEN
$7.03B
$5.8M 0.26%
110,000
– –
XLRN
86
DELISTED
Acceleron Pharma
XLRN
$5.61M 0.25%
128,900
– –
FENC icon
87
Fennec Pharmaceuticals
FENC
$344M
$4.59M 0.2%
720,000
-21,175
-3% -$148K
UROV
88
DELISTED
Urovant Sciences Ltd.
UROV
$4.41M 0.2%
669,000
+74,184
+12% +$675K
ORTX
89
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.25M 0.19%
+27,000
New +$4.03M
VYGR icon
90
Voyager Therapeutics
VYGR
$189M
$4.1M 0.18%
436,000
-267,425
-38% -$3.43M
PTCT icon
91
PTC Therapeutics
PTCT
$6.26B
$3.88M 0.17%
113,000
-131,000
-54% -$4.71M
CRNX icon
92
Crinetics Pharmaceuticals
CRNX
$8.85B
$3.7M 0.16%
123,225
– –
LKFT
93
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$3.67M 0.16%
40,000
– –
ADVM
94
DELISTED
Adverum Biotechnologies
ADVM
$3.61M 0.16%
+114,658
New +$4.66M
ETTX
95
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$3.48M 0.15%
879,541
+106,985
+14% +$705K
VBIV
96
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$2.96M 0.13%
61,667
– –
ARQL
97
DELISTED
Arqule Inc
ARQL
$2.95M 0.13%
+1,066,000
New +$4.07M
XENE icon
98
Xenon Pharmaceuticals
XENE
$6.2B
$2.68M 0.12%
424,433
+109,433
+35% +$973K
GTT
99
DELISTED
GTT Communications, Inc.
GTT
$2.67M 0.12%
112,991
-328,009
-74% -$11M
BEP icon
100
Brookfield Renewable
BEP
$9.9B
$2.67M 0.12%
193,280
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Eventide Asset Management held 158 positions worth $2.26B, down 17% from $2.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Eventide Asset Management deployed $97.5M of net new capital in Q4 2018, opening 12 new positions and adding to 35 existing holdings. Its largest new stake was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Macquarie Infrastructure Holdings, LLC, an estimated $19.7M trimmed.

  • Eventide Asset Management's largest Q4 2018 buy was Talend S.A. American Depositary Shares: 388,033 shares worth $14.4M.
  • Eventide Asset Management added most to Sage Therapeutics in Q4 2018, an estimated $50.6M increase.
  • Eventide Asset Management's biggest Q4 2018 reduction was Macquarie Infrastructure Holdings, LLC, cutting an estimated $19.7M.
  • Eventide Asset Management fully exited AnaptysBio in Q4 2018, selling an estimated $26.2M.
  • Eventide Asset Management's ten largest holdings make up 31% of its $2.26B portfolio in Q4 2018.
  • Eventide Asset Management opened 12 new positions and closed 24 in Q4 2018.
  • Eventide Asset Management's portfolio value fell 17% quarter-over-quarter to $2.26B.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.